Earnings Outlook: Pfizer earnings: Looking toward an ambitious 2022 agenda

Pfizer Inc. is keeping busy.

The behemoth New York, NY-based drugmaker PFE, +2.08% expects to have between 25 and 30 new drug approvals through 2022, including several potential blockbusters that could get approved by 2020.

Following through with that agenda will be key for Pfizer, since it is also scheduled to lose patent exclusivity on a number of valuable products in the next few years.

When the company reports third-quarter earnings, scheduled for Tuesday before the open, expect an update on that ambitious agenda, especially as that 2020 deadline draws closer.

>>> Original Source <<<